このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

成人末梢動脈疾患患者における第XI因子阻害による有害血管転帰の低減 (ROXI-PALISADE)

2026年11月3日 更新者:Regeneron Pharmaceuticals

REGN7508およびREGN9933(第XI因子に対するモノクローナル抗体)の有効性および安全性を、症状のある末梢動脈疾患のため最近下肢血行再建術を受けた参加者において評価するための第3相多施設共同無作為化試験のマスタープロトコル(ROXI-PALISADE)

This study is researching 2 different experimental drugs called REGN7508 and REGN9933. The study is focused on people who have Peripheral Artery Disease (PAD), which means that the blood vessels in their arms and legs have become too narrow. People with PAD have a higher risk of getting blood clots after procedures like Lower Extremity Revascularization (LER), a procedure to improve blood flow in the legs and feet.

The aim of this study is to see how well REGN7508 and REGN9933 prevent life-threatening blood clots in participants with PAD who have recently had LER. The effects of REGN7508 and REGN9933, individually, will also be compared to rivaroxaban and a placebo.

The study is looking at several other research questions, including:

  • What side effects might happen from taking the study drugs and how do they compare to the side effects of rivaroxaban
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects)
  • If the study drugs affect the ability of the blood to clot normally

調査の概要

研究の種類

介入

入学 (推定)

7050

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Alabama
      • Alexander City、Alabama、アメリカ、35010
        • 募集
        • Lake Martin Medical and Vascular Center
      • Alexander City、Alabama、アメリカ、35010
        • 募集
        • Advanced Cardiovascular
    • Arizona
      • Avondale、Arizona、アメリカ、85392
        • 募集
        • Axsendo Clinical Research, Integrated Medical Services
    • Arkansas
      • Little Rock、Arkansas、アメリカ、72205
        • 募集
        • Applied Research Center of Arkansas
    • California
      • Los Angeles、California、アメリカ、90010
        • 募集
        • Angel City Research, Inc.
      • Oxnard、California、アメリカ、93036
        • 募集
        • Pacific Cardiovascular and Vein Institute
      • West Hills、California、アメリカ、91307
        • 募集
        • Interventional Cardiology Medical Group
    • Florida
      • Crystal River、Florida、アメリカ、34429
        • 募集
        • Nature Coast Clinical Research - Cardiology
      • Jacksonville、Florida、アメリカ、32209
        • 募集
        • University of Florida (UF) Health Jacksonville Clinical Center
      • Miami Lakes、Florida、アメリカ、33014
        • 募集
        • Inpatient Research Clinic LLC
      • Panama City、Florida、アメリカ、32405
        • 募集
        • Cardiovascular Institute of Northwest Florida, Main Office
      • Tampa、Florida、アメリカ、33614
        • 募集
        • Tampa Cardiovascular Interventions and Research
    • Indiana
      • Fort Wayne、Indiana、アメリカ、46804
        • 募集
        • Lutheran Medical Group LLC dba Lutheran Health Physicians
      • Hammond、Indiana、アメリカ、46324
        • 募集
        • ASHA Clinical Research Munster, LLC
      • Munster、Indiana、アメリカ、46321
        • 募集
        • Profound Research, Powers Health Medical Group
    • Louisiana
      • Shreveport、Louisiana、アメリカ、71103
        • 募集
        • Cardiovascular Solutions
    • Mississippi
      • Petal、Mississippi、アメリカ、39465
        • 募集
        • Rovia Clinical Research - Hattiesburg Clinic
    • New Jersey
      • Flemington、New Jersey、アメリカ、08822
        • 募集
        • Advanced Heart and Vascular Institute of Hunterdon
    • New York
      • Valhalla、New York、アメリカ、10595
        • 募集
        • Westchester Medical Center
    • North Carolina
      • Charlotte、North Carolina、アメリカ、28207
        • 募集
        • Mecklenburg Heart Specialists Vascular Institute and Vein Center
      • Mooresville、North Carolina、アメリカ、28117
        • 募集
        • Accellacare of Piedmont, Piedmont Healthcare
    • Oklahoma
      • Oklahoma City、Oklahoma、アメリカ、73102
        • 募集
        • Hightower Clinical
    • South Dakota
      • Rapid City、South Dakota、アメリカ、57701
        • 募集
        • Monument Health Clinical Research
    • Tennessee
      • Jackson、Tennessee、アメリカ、38301
        • 募集
        • Apex Research Foundation, LLC
      • Knoxville、Tennessee、アメリカ、37934
        • 募集
        • Tennova TCMC
      • Tullahoma、Tennessee、アメリカ、37388
        • 募集
        • Vanderbilt Heart and Vascular Tullahoma, Cardiology and Vascular Associates
    • Texas
      • Amarillo、Texas、アメリカ、79106
        • 募集
        • PharmaTex Research
      • Cypress、Texas、アメリカ、77429
        • 募集
        • Vital Heart and Vein
      • DeSoto、Texas、アメリカ、75115
        • 募集
        • Epic Medical Research
      • Plano、Texas、アメリカ、75093
        • 募集
        • Epic Medical Research-Plano
      • Doncaster、イギリス、DN2 5LT
        • 募集
        • Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust
      • London、イギリス、W6 8RF
        • 募集
        • Charing Cross Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Key Inclusion Criteria:

  1. Successful LER distal to the external iliac artery for ischemia due to atherosclerotic disease within 10 days prior to randomization as described in the protocol

  2. At least 1 of the following enrichment factors for major thrombotic vascular events:

    1. Bypass with prosthetic graft
    2. Endovascular treatment with stenting
    3. Target lesion length >15 cm
    4. History of LER or amputation for PAD prior to qualifying LER
    5. Type 2 diabetes mellitus requiring pharmacologic treatment
    6. Comorbid symptomatic coronary artery disease as described in the protocol
    7. Chronic kidney disease as described in the protocol
    8. Age ≥75 years

Key Exclusion Criteria:

  1. Has any active clinical condition requiring chronic therapeutic anticoagulation after the index revascularization including known triple positive antiphospholipid syndrome
  2. Has known bleeding diathesis, platelet count <50,000/mm^3 or history of non-traumatic intracerebral hemorrhage, known cerebral amyloid angiopathy, or known unrepaired cerebrovascular malformations
  3. Has recent coronary revascularization as described in the protocol
  4. For Cohort 2 only: Has estimated Glomerular Filtration Rate (eGFR) <15 mL/min/1.73m^2 within 14 days prior to randomization or on dialysis or expected to be started on dialysis within the next 12 weeks starting from randomization
  5. Has any other condition or therapy which would make the participant unsuitable for this study or not allow participation for the full planned study period
  6. Has allergy, hypersensitivity, or other contraindication to REGN7508, REGN9933, or rivaroxaban (Cohort 2 only) or their excipients

Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:コホート1

Administered per the protocol

Administered per the protocol

他の名前:
  • cenvacibart

Administered per the protocol

他の名前:
  • amrecibart
実験的:コホート 2

Administered per the protocol

他の名前:
  • cenvacibart

Administered per the protocol

他の名前:
  • amrecibart

Administered per the protocol

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Time-to-first occurrence of a major thrombotic vascular event, consisting of Acute Limb Ischemia (ALI), major amputation (above the ankle) of vascular etiology, Myocardial Infarction (MI), ischemic stroke, or Cardiovascular (CV) death
時間枠:Approximately up to 42 months

Cohort 1

Approximately up to 42 months
Time-to-first occurrence of International Society of Thrombosis and Hemostasis (ISTH) major or Clinically Relevant Non-major (CRNM) bleeding
時間枠:Approximately up to 42 months

Cohort 1 and 2

Approximately up to 42 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Total (first and subsequent) occurrences of major thrombotic vascular events, consisting of ALI, major amputation (above the ankle) of vascular etiology, MI, ischemic stroke, or CV death
時間枠:Approximately up to 42 months

Cohort 1 and 2

Approximately up to 42 months
Time-to-first occurrence of an expanded thrombotic vascular event, consisting of ALI, major amputation (above the ankle) of vascular etiology, MI, ischemic stroke, CV death, unplanned index limb revascularization, or Venous Thromboembolism (VTE)
時間枠:Approximately up to 42 months

Cohort 1 and 2

Approximately up to 42 months
Time-to-first occurrence of ALI, major amputation (above the ankle) of vascular etiology, MI, ischemic stroke or coronary death
時間枠:Approximately up to 42 months

Cohort 1

Approximately up to 42 months
Time-to-first occurrence of vascular hospitalization for a coronary cerebrovascular, or peripheral event of thrombotic nature
時間枠:Approximately up to 42 months

Cohort 1

Approximately up to 42 months
Time-to-first occurrence of ALI, major amputation of vascular etiology, MI, ischemic stroke, or all-cause mortality
時間枠:Approximately up to 42 months

Cohort 1

Approximately up to 42 months
Time-to-first occurrence of unplanned index limb revascularization for ischemia
時間枠:Approximately up to 42 months

Cohort 1

Approximately up to 42 months
Time-to-first occurrence of VTE
時間枠:Approximately up to 42 months

Cohort 1

Approximately up to 42 months
Time-to-all-cause mortality
時間枠:Approximately up to 42 months

Cohort 1

Approximately up to 42 months
Time-to-first occurrence of Major Adverse Limb Event (MALE)
時間枠:Approximately up to 42 months

Cohort 1

Approximately up to 42 months
Time-to-first occurrence of Major Adverse Cardiovascular Event (MACE)
時間枠:Approximately up to 42 months

Cohort 1

Approximately up to 42 months
Time-to-first occurrence of a major thrombotic vascular event or ISTH fatal/critical organ bleeding (net clinical benefit)
時間枠:Approximately up to 42 months

Cohort 1

Approximately up to 42 months
Time-to-first occurrence of Thrombolysis in Myocardial Infarction (TIMI) major bleeding
時間枠:Approximately up to 42 months

Cohort 1 and 2

Approximately up to 42 months
Occurrence of Treatment-Emergent Adverse Event (TEAEs)
時間枠:Approximately up to 45 months

Cohort 1 and 2

Approximately up to 45 months
Severity of TEAEs
時間枠:Approximately up to 45 months

Cohort 1 and 2

Approximately up to 45 months
Occurrence of Anti-Drug Antibody (ADA) to REGN7508 over time
時間枠:Approximately up to 45 months

Cohort 1 and 2

Approximately up to 45 months
Magnitude of ADA to REGN7508 over time
時間枠:Approximately up to 45 months

Cohort 1 and 2

Approximately up to 45 months
Occurrence of ADA to REGN9933 over time
時間枠:Approximately up to 45 months

Cohort 1 and 2

Approximately up to 45 months
Magnitude of ADA to REGN9933 over time
時間枠:Approximately up to 45 months

Cohort 1 and 2

Approximately up to 45 months
Concentrations of REGN7508 over time
時間枠:Approximately up to 45 months

Cohort 1 and 2

Approximately up to 45 months
Concentrations of REGN9933 over time
時間枠:Approximately up to 45 months

Cohort 1 and 2

Approximately up to 45 months
Change from baseline in activated Partial Thromboplastin Time (aPTT) over time
時間枠:Approximately up to week 9

Cohort 1 and 2

Approximately up to week 9
Change from baseline in Prothrombin Time (PT)/International Normalization Ratio (INR) over time
時間枠:Approximately up to week 9

Cohort 1 and 2

Approximately up to week 9
Total (first and subsequent) occurrences of expanded thrombotic vascular events
時間枠:Approximately up to 42 months

Cohort 2

Approximately up to 42 months
Time-to-first occurrence of a major thrombotic vascular event
時間枠:Approximately up to 42 months

Cohort 2

Approximately up to 42 months
Total (first and subsequent) occurrences of ALI, major amputation (above the ankle) of vascular etiology, MI, all-cause stroke, or CV death
時間枠:Approximately up to 42 months

Cohort 2

Approximately up to 42 months
Total (first and subsequent) occurrences of ALI, major amputation (above the ankle) of vascular etiology, MI, all-cause stroke, CV death, unplanned index limb revascularization, or VTE
時間枠:Approximately up to 42 months

Cohort 2

Approximately up to 42 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Clinical Trial Management、Regeneron Pharmaceuticals

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年7月10日

一次修了 (推定)

2029年8月18日

研究の完了 (推定)

2029年11月16日

試験登録日

最初に提出

2026年1月2日

QC基準を満たした最初の提出物

2026年1月2日

最初の投稿 (実際)

2026年1月6日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月5日

QC基準を満たした最後の更新が送信されました

2026年11月3日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

IPD 共有時間枠

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

IPD 共有アクセス基準

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する